Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform -- an engine for new cures -- to dramatically improve patients' lives.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/30/20	$30,000,000	Seed	Nolan Capital PBM Capital Group	undisclosed
08/06/20	$95,000,000	Series B	ArrowMark Partners BlackRock Casdin Capital Fidelity Research and Management Company Franklin Templeton GV Invus Octagon Capital PBM Capital Group Perceptive Advisors Sands Capital Venrock Healthcare Partners	undisclosed